Systemic gamma-interferon therapy for recurrent gliomas
- 1 December 1988
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 69 (6) , 826-829
- https://doi.org/10.3171/jns.1988.69.6.0826
Abstract
Recombinant gamma-interferon (2 mg/sq m) was administered intravenously twice weekly in 8-week courses to 14 patients with recurrent gliomas. Computerized tomography (CT) evidence of response was seen in only one patient, and stabilization for 12 to 86 weeks was recorded in three. This was a disappointing result, particularly in a series of patients with relatively small initial tumor volumes (less than 50 cu mm on enhanced CT) and Karnofsky functional ratings of 70 or higher. In addition, several instances of toxicity potentially attributable to gamma-interferon were observed.Keywords
This publication has 16 references indexed in Scilit:
- Phase II trial of interferon-β for treatment of recurrent glioblastoma multiformeJournal of Neurosurgery, 1986
- Immunobiology of primary intracranial tumorsJournal of Neurosurgery, 1985
- Interferon-β in patients with low-grade astrocytomas — A phase I studyJournal of Neuro-Oncology, 1985
- Response of glioma cells to interferon‐gamma: increase in class II RNA, protein and mixed lymphocyte reaction‐stimulating abilityEuropean Journal of Immunology, 1985
- Clinical effect of interferon in malignant brain tumoursNeurosurgical Review, 1984
- Effects of Interferon on Growth Rate and Radiation Sensitivity of Cultured, Human Glioma CellsActa Radiologica: Oncology, 1982
- Block of a glioma cell line in S by interferonInternational Journal of Cancer, 1981